AbCellera Biologics Inc (ABCL) concluded trading on Wednesday at a closing price of $2.39, with 4.39 million shares of worth about $10.48 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.64% during that period and on March 05, 2025 the price saw a gain of about 2.14%. Currently the company’s common shares owned by public are about 295.16M shares, out of which, 223.90M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Stock saw a price change of -18.15% in past 5 days and over the past one month there was a price change of -22.40%. Year-to-date (YTD), ABCL shares are showing a performance of -18.43% which decreased to -52.67% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.20 but also hit the highest price of $5.12 during that period. The average intraday trading volume for AbCellera Biologics Inc shares is 3.77 million. The stock is currently trading -19.86% below its 20-day simple moving average (SMA20), while that difference is down -21.55% for SMA50 and it goes to -18.87% lower than SMA200.
AbCellera Biologics Inc (NASDAQ: ABCL) currently have 295.16M outstanding shares and institutions hold larger chunk of about 37.06% of that.
The stock has a current market capitalization of $712.19M and its 3Y-monthly beta is at 0.47. It has posted earnings per share of -$0.60 in the same period. It has Quick Ratio of 9.34 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABCL, volatility over the week remained 10.02% while standing at 7.44% over the month.
Stock’s fiscal year EPS is expected to drop by -10.53% while it is estimated to decrease by -6.97% in next year.
Coverage by The Benchmark Company stated AbCellera Biologics Inc (ABCL) stock as a Buy in their note to investors on February 22, 2024, suggesting a price target of $9 for the stock. Stock get an Overweight rating from Piper Sandler on October 13, 2023.
